

AUSTRALIA
Patents Act 1990

662382⁵
P/00/001 2/5/91
Section 29

PATENT REQUEST: STANDARD PATENT/PATENT OF ADDITION

We, being the person identified below as the Applicant, request the grant of a patent to the person identified below as the Nominated Person, for an invention described in the accompanying standard complete specification.

Full application details follow.

- [71] Applicant: HOECHST AKTIENGESELLSCHAFT
Address: D-6230 FRANKFURT/MAIN 80, FEDERAL REPUBLIC OF GERMANY
- [70] Nominated Person: HOECHST AKTIENGESELLSCHAFT
Address: D-6230 FRANKFURT/MAIN 80, FEDERAL REPUBLIC OF GERMANY
- [54] Invention Title: NOVEL ARYLCYCLOALKYL DERIVATIVES THEIR PRODUCTION AND THEIR USE
- [72] Name(s) of actual inventor(s): RAMACHANDRA GANAPATI NAIK, VILAS NARAYAN MUMBAIKAR, RANGARAJAN VASUMATHY, AFTAB DAWOODBHAI LAKDAWALA, MANDAKINI VITHALRAO SHIROLE, BANSI LAL, JURGEN BLUMBACH, KLAUS ULRICH WEITHMANN, ROBERT RYDER BARTLETT
- [74] Address for service in Australia: c/o WATERMARK PATENT & TRADEMARK ATTORNEYS, of The Atrium, 290 Burwood Road, Hawthorn, Victoria 3122, Australia
Attorney Code: WM

BASIC CONVENTION APPLICATION(S) DETAILS

- | [31] Application Number | [33] Country | Country Code | [32] Date of Application |
|-------------------------|--------------|--------------|--------------------------|
| 92 100 664.9 | EUROPE | EP | 16TH JANUARY 1992 |
| (German designation) | | | |
- Drawing number recommended to accompany the abstract

By our Patent Attorneys,
WATERMARK PATENT & TRADEMARK ATTORNEYS


.....

Darryl B. Mischlewski

Registered Patent Attorney

DATED this 14th day of January 1993.

F040480 15/01/93

AUSTRALIA

Patents Act 1990

NOTICE OF ENTITLEMENT

(To be filed before acceptance)


We, **HOECHST AKTIENGESELLSCHAFT**, of D-6230 Frankfurt /Main 80, Federal Republic of Germany, being the applicant in respect of Application No. 31847/93 state the following:-

The Person nominated for the grant of the patent has entitlement from the actual inventors by assignment.

The person nominated for the grant of the patent is the applicant of the basic application listed on the patent request form.

The basic application listed on the request form is the first application made in a Convention country in respect of the invention.

By our Patent Attorneys,
WATERMARK PATENT & TRADEMARK ATTORNEYS


.....
Darryl B. Mischlewski
Registered Patent Attorney

DATED 15 June 1995

14010 989 00



AU9331847


(12) PATENT ABRIDGMENT (11) Document No. AU-B-31847/93
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 662382

- (54) Title
NOVEL ARYLCYCLOALKYL DERIVATIVES THEIR PRODUCTION AND THEIR USE
- (51)⁵ International Patent Classification(s)
C07C 049/252 A61K 031/12 C07C 045/46 C07C 045/74
C07C 227/16 C07C 229/08 C07D 307/46 C07D 333/22
- (21) Application No. : 31847/93 (22) Application Date : 15.01.93
- (30) Priority Data
- (31) Number (32) Date (33) Country
92100664 16.01.92 EP EUROPEAN PATENT OFFICE (EPO)
- (43) Publication Date : 22.07.93
- (44) Publication Date of Accepted Application : 31.08.95
- (71) Applicant(s)
HOECHST AKTIENGESellschaft
- (72) Inventor(s)
RAMACHANDRA GANAPATI NAIK; VILAS NARAYAN MUMBAIKAR; RANGARAJAN VASUMATHY;
AFTAB DAWOODBHAI LAKDAWALA; MANDAKINI VITHALRAO SHIROLE; BANSI LAL; JURGEN
BLUMBACH; KLAUS ULRICH WEITHMANN; ROBERT RYDER BARTLETT
- (74) Attorney or Agent
WATERMARK PATENT & TRADEMARK ATTORNEYS, Locked Bag 5, HAWTHORN VIC 3122
- (57)

The compounds of the invention, alone or in the form of a suitable formulation, are thus useful as medicaments in the treatment of inflammatory conditions, in particular chronic inflammatory conditions such as rheumatoid arthritis, osteoarthritis, asthma and malignancies.

Claim

1. Compounds of formula I




wherein

R₁ denotes C₁-C₆-alkyl, substituted C₁-C₆-alkyl, C(O)O-C₁-C₄-alkyl, C(O)OH, or


(11) AU-B-31847/93
(10) 662382

-2-

a residue selected from



wherein R_5 is one, two, three or four of the residues which are independent from each other H, C_1 - C_6 -alkyl, substituted C_1 - C_6 -alkyl, hydroxy, C_1 - C_6 -alkoxy, C_1 - C_4 -alkyl-carboxy, cyano, $-NHC(O)C_1$ - C_3 -alkyl, $-OC_1$ - C_3 -alkyl-phenyl, $-OCH_2-O-O-C_1$ - C_4 -alkyl, $-O-C(O)-C_1$ - C_4 -alkyl, $-C(O)-O-C_1$ - C_4 -alkyl, halogens, amino, nitro, $-NH$ - C_1 - C_4 -alkyl, $-N-(C_1$ - C_4 -alkyl) $_2$ and $-C_1$ - C_4 -alkyl- R_6 wherein R_6 is a residue selected from




- X is O, S, N-H, N- C_1 - C_6 -alkyl;
 R_2 is H, C_1 - C_6 -alkyl, $-C(O)-C_1$ - C_6 -alkyl;
 R_3 is one, two or three of the residues which are independent from each other H, C_1 - C_6 -alkyl, $-C(O)-C_1$ - C_6 -alkyl, $-C(O)-O-C_1$ - C_6 -alkyl, OH, O- C_1 - C_6 -alkyl, $-O-C(O)-C_1$ - C_6 -alkyl, halogen;
 R_4 is H, $-OH$, $-O-C_1$ - C_6 -alkyl, $-O-C(O)-C_1$ - C_6 -alkyl, $-C(O)-OH$, $-C(O)-O-C_1$ - C_6 -alkyl,

(11) AU-B-31847/93

-3-

(10) 662382



n = 0, 1 or 2 and

'a' represents an optional additional single bond.

AUSTRALIA

Patents Act 1990

662382

**ORIGINAL
COMPLETE SPECIFICATION
STANDARD PATENT**

Application Number:

Lodged:

Invention Title:

NOVEL ARYLCYCLOALKYL DERIVATIVES THEIR PRODUCTION AND
THEIR USE

The following statement is a full description of this invention, including the
best method of performing it known to :-US

Specification


5 Novel arylcycloalkyl derivatives their production and their use

The present invention relates to novel arylcycloalkyl derivatives their production and their use.

10

The chalcones of the following general formula Ia are known by the following prior art:

15



(Ia)

1. (J.P. 281022) Compounds of formula Ia, wherein

R_1 = substituted phenyl

R_2 = OH

a = single or double bond

R_3 = OH

R_{4a} = H, isoprenyl or isopentyl

are effective in treatment of diseases caused by hypersecretion of androgens, e.g. prostatomegaly, alopecia in males, acne vulgaris or seborrhoea.

30

2. J.P. 026775 Compounds of formula Ia wherein

R_1 = substituted phenyl

R_2 = H, OH, acetoxy, carboxymethoxy or methoxycarbonylmethoxy

R_3 = OH, methoxy, benzyloxy, H

R_{4a} = H, isoprenyl, isopentyl

possess anti-hyaluronidase activity.

3. J.P. 142166 Compounds of formula Ia wherein

5

R_1 = substituted phenyl

R_2 = OH, acetoxy, carboxymethoxy, methoxycarboxylmethoxy,

R_3 = OH, methoxy, H

a = single or a double bond

R_{4a} = isoprenyl, isopentyl, n-propyl or H,

10

are useful as aldose reductase inhibitors - used to treat diabetic complications such as cataracts, retinitis, nerve disorder or kidney disease.

4. J.P. 248389 Compounds of formula Ia wherein

15

R_1 = substituted phenyl

R_2 = OH

R_3 = OH

a = double bond

R_{4a} = H

20

are useful as aldose reductase inhibitors - for treatment of diabetes mellitus complications.

5. J.P. 144717 Compounds of formula Ia wherein

R_1 = substituted phenyl

R_2 = H or OH

R_3 = H or OH

a = double bond

R_{4a} = H or OH

are useful as c-kinase inhibitors and antitumor agents.

30

6. EP 150166 Compounds of formula Ia wherein

R_1 = substituted phenyl

R_2 = H, halogen, lower alkyl, lower alkoxy, CN, carboxy, nitro,

R_3 = H, halogen, lower alkyl, lower alkoxy, CN, carboxy, nitro, hydroxy, substituted acetic acid derivative,

a = double bond

R_{4a} = as in R_3

- 5 having inhibitory effect on hydroxy-prostaglandin dehydrogenase. They may have potential local activity against gastrointestinal disorders such as gastric ulcer, and ulcerative colitis. Other potential fields of application include the treatment of rheumatoid arthritis, circulatory disorders, cancer, lack of fertility and cell regulation.

10

7. J.P. 167288 Compounds of formula Ia wherein

R_1 = substituted phenyl

R_2 = H

R_3 = OH,

a = single bond


R_{4a} = OH

are selective inhibitors of 5-lipoxygenase and have excellent anti-allergic activity, thus are useful as a safe anti-allergic drug such as antiasthmatic, antiphlogistic and immune activating drug.

15

20


The present invention relates to compounds of formula I, wherein




(1)

30

R_1 = C_1 - C_6 -alkyl, substituted C_1 - C_6 -alkyl, $C(O)O$ - C_1 - C_4 -alkyl, $C(O)OH$, or a residue selected from



wherein R₅ is one, two, three or four of the residues which are independent from each other H, C₁-C₆-alkyl, substituted C₁-C₆-alkyl, hydroxy, C₁-C₆-alkoxy, C₁-C₄-alkyl-carboxy, cyano, -NHC(O)C₁-C₃-alkyl, -OC₁-C₃-alkyl-phenyl, -OCH₂-O-O-C₁-C₄-alkyl, -O-C(O)-C₁-C₄-alkyl, -C(O)-O-C₁-C₄-alkyl, halogens, amino, nitro, -NH-C₁-C₄-alkyl, -N-(C₁-C₄-alkyl)₂ and -C₁-C₄-alkyl-R₆ wherein R₆ is a residue selected from




X is O, S, N-H, N-C₁-C₆-alkyl;

R₂ is H, C₁-C₆-alkyl, -C(O)-C₁-C₆-alkyl;

R₃ is one, two or three of the residues which are independent from each other H, C₁-C₆-alkyl, -C(O)-C₁-C₆-alkyl, -C(O)-O-C₁-C₆-alkyl, OH, O-C₁-C₆-alkyl, -O-C(O)-C₁-C₆-alkyl, halogen;


R₄ is H, -OH, -O-C₁-C₆-alkyl, -O-C(O)-C₁-C₆-alkyl, -C(O)-OH, -C(O)-O-C₁-C₆-alkyl,



$n = 0, 1 \text{ or } 2$ and


5 'a' represents an optional additional single bond.

Preferred compounds are compounds of formula II




wherein R_1, R_2, R_3, R_4 and a are as previously defined.


Among this group of compounds those are preferred, in which R_1 is



R_5 denoting H, $\text{C}_1-\text{C}_6\text{-alkyl}$, substituted $\text{C}_1-\text{C}_6\text{-alkyl}$, hydroxy, $\text{C}_1-\text{C}_3\text{-alkoxy}$, halogen, $\text{C}_1-\text{C}_4\text{-alkyl}-R_6$ wherein R_6 stands for




or



R_4 denotes H, OH or $-O-\overset{\overset{O}{\parallel}}{C}-(C_1-C_4\text{-alkyl})-NH_2$;

X stands for O, NH, S, N-C₁-C₆-alkyl and a stands for an optional additional bond.

Particularly preferred are compounds of formula III



wherein

R_2 is H or C₁-C₃-alkyl,

R_5 denotes one or two halogens or one or two C₁-C₆-alkyl or C₁-C₃-alkoxy groups and a denotes an optional additional single bond.

- 10 The above term substituted alkyl, preferably C₁-C₃-alkyl, means alkyl substituted by preferably one halogen, hydroxy, C₁-C₃-alkoxy, amino, C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)-amino, carbonyl or carboxy-C₁-C₄-alkyl.

The compounds of the invention contain two asymmetric centers, designated with asterisks in formula II, at the points of attachment of R_4 , (e.g. formula II,


- 15 when $R_4 = H$) and of the aryl group on the carbocyclic ring; therefore, four isomers are possible, designated individually as the cis-(+), cis(-), trans-(+), and trans(-) forms. The present invention includes each of the four isomers individually or as mixtures of two or more of the four isomers.

Examples of particularly preferred compounds are:


1. trans-(+/-)-2-[4,6-Dimethoxy-2-hydroxy-3-(3-(4-chlorophenyl))prop-2-enoyl]-phenylcyclohexanol.
2. trans-(+/-)-2-[4,6-Dimethoxy-2-hydroxy-3-(3-(2-chlorophenyl))prop-2-enoyl]-phenylcyclohexanol.
- 5 3. trans-(+/-)-2-[4,6-Dimethoxy-2-hydroxy-3-(3-(3-chlorophenyl))prop-2-enoyl]-phenylcyclohexanol.
4. trans-(+/-)-2-[4,6-Dimethoxy-2-hydroxy-3-(3-(2-bromophenyl))prop-2-enoyl]-phenylcyclohexanol.
5. trans-(+/-)-2-[4,6-Dimethoxy-2-hydroxy-3-(3-(3-bromophenyl))prop-2-enoyl]-phenylcyclohexanol.
- 10 6. trans-(+/-)-2-[4,6-Dimethoxy-2-hydroxy-3-(3-(4-bromophenyl))prop-2-enoyl]-phenylcyclohexanol.
7. trans-(+/-)-2-[4,6-Dimethoxy-2-hydroxy-3-(3-(4-fluorophenyl))prop-2-enoyl]-phenylcyclohexanol.
- 15 8. trans-(+/-)-2-[4,6-Dimethoxy-2-hydroxy-3-(3-(2-methylphenyl))prop-2-enoyl]-phenylcyclohexanol.
9. trans-(+/-)-2-[4,6-Dimethoxy-2-hydroxy-3-(3-(4-methylphenyl))prop-2-enoyl]-phenylcyclohexanol.
10. trans-(+/-)-2-[4,6-Dimethoxy-2-hydroxy-3-(3-(2,3-dichlorophenyl))prop-2-enoyl]-phenylcyclohexanol.
- 20 11. trans-(+/-)-2-[4,6-Dimethoxy-2-hydroxy-3-(3-(2,6-dichlorophenyl))prop-2-enoyl]-phenylcyclohexanol.
12. trans-(+/-)-2-[4,6-Dimethoxy-2-hydroxy-3-(3-(2,6-dichlorophenyl))prop-2-enoyl]phenylcyclohexanol.

13. trans-(+)-2-[4,6-Dimethoxy-2-hydroxy-3-(3-(4-chlorophenyl)) prop-2-enoyl]phenylcyclohexanol.
14. trans-(-)-2-[4,6-Dimethoxy-2-hydroxy-3-(3-(4-chlorophenyl)) prop-2-enoyl]phenylcyclohexanol.
15. trans-(+/-)-2-[4,6-Dimethoxy-2-hydroxy-3-(3-(3-methoxy phenyl))prop-2-enoyl]phenylcyclohexanol.
16. trans-(-)-2-[4,6-Dimethoxy-2-hydroxy-3-(3-(3-methoxyphenyl)) prop-2-enoyl]phenylcyclohexanol.
17. trans-(+/-)-2-[4,6-Dimethoxy-2-hydroxy-3-(3-(4-chloro-3-nitro phenyl)) prop-2-enoyl]phenylcyclohexanol.
18. trans-(-)-2-[4,6-Dimethoxy-2-hydroxy-3-(3-(4-chloro-3-nitro phenyl)) prop-2-enoyl]phenylcyclohexanol.
19. trans-(+/-)-1-[4,6-Dimethoxy-2-hydroxy-3-(2-β-amino)acetoxy)cyclohexyl]phenyl-1-(3-(3,4-dimethoxy)phenyl)propanone hydrochloride.


A further subject of the instant application is a process for the production of compounds of formula 1 as described above wherein a compound of formula V



- A) is converted into a compound of formula VI, R_4 denoting OH



- 10 by treatment with a borane-solvent-complex followed by oxidation or
- B) to get a compound of formula VI, a compound of formula V is treated with a peracid and the epoxide thus produced is treated with a hydride reagent or
- C) the compound of formula VI is produced by condensation of a suitable arene with cyclohexene oxide in the presence of an acid catalyst and
- 15 D) a compound of formula VI is treated with acetic anhydride and a mineral acid to give a compound of formula VII,




- 25
- wherein R_2 is methyl and R_4 is O-C(O)-Me and
- E) a compound of formula VII as described under D) is demethylated by treatment with a Lewis acid or a demethylating agent to give a compound of formula VII R_2 denoting H and R_4 denoting OC(O)Me and
- 30

- F) a compound of formula VII R_2 denoting H and R_4 denoting OH is produced by treatment of a compound produced under E) with dilute alkali, and
- G) the compound of formula VII is converted into a compound of formula I (a = additional bond) by treatment with an appropriate aldehyde in the presence of a base and the compound of formula I (a = no additional bond) is produced by hydrogenation of the compound of formula I (a = additional bond), R_1 , R_2 and R_3 where not explained explicitly having the meaning as indicated above.

10 The compounds of formula V are prepared by methods known to a person skilled in the art. Typically they are prepared by addition of aryllithiums of formula IV to cyclohexanone followed by acid catalyzed dehydration, R_2 and R_3 having the meaning as indicated above.

15



20

A suitable borane-solvent complex for step A of the above sequence is for instance borane-tetrahydrofuran or borane dimethylsulfide. The oxidation can be carried out using alkaline hydrogen peroxide. A suitable peracid for step B is for instance chloroperbenzoic acid. An example for a suitable hydride reagent is lithium aluminium hydride.

25

Step C can be carried out using as arene 1,3,5-trimethoxybenzene for example the acid catalyst being aluminium chloride.

30

The mineral acid needed for step D can be for instance phosphoric acid.

30


Step E can be carried out using for example as Lewis acid boron tribromide and as demethylating agent metal thiolates. The preferred dilute alkali for step F) is 2N sodium hydroxide solution.

The base in the presence of which step G is carried out can be sodium hydroxide for example.

The products according to the above reaction steps can be used for further reactions to compounds according to the instant invention. Most of said reactions can be carried out according to procedures described in European patent application 0 241 003. Additional information about starting products, intermediates and derivatization reactions can be obtained from the patent literature mentioned in the introduction.

The physical constants of some of the preferred compounds of the present invention are listed in Table 1.

Table 1



Compound No.	R ₅	R ₂	a	mp °C	Sign of Rotation
1.	H	H	2',3'	183-185	
2.	2-Cl	H	"	204-206	
3.	3-Cl	H	"	170	
4.	4-Cl	H	"	221	
5.	2-Br	H	"	203	
6.	3-Br	H	"	171	
7.	4-Br	H	"	222	
8.	4-F	H	"	215-216	
9.	2,3-Cl ₂	H	"	216	
10.	2,4-Cl ₂	H	"	226-228	
11.	2,6-Cl ₂	H	"	197	
12.	2-Me	H	"	199	
13.	4-Me	H	"	213	
14.	4-OMe	H	"	210	
15.	4-Cl	Me	"	175	
16.	4-Cl	H	H,H	190	
17.	4-F	H	H,H	169	
18.	3,4-Cl ₂	H	Δ 2',3'	202	±
19.	3,5-Cl ₂	H	"	227	"
20.	2-OMe	H	"	215	"
21.	3-OMe		"	178	"
22.	3,4-(OMe) ₂	H	"	194	"
23.	2,5-(OMe) ₂	H	"	185	"
24.	2,4-(OMe) ₂	H	"	224-225	"
25.	2,4,6-(OMe) ₃	H	"	162	"
26.	4-COOH	H	"	240	"
27.	4-N(CH ₃) ₂	H	"	187	"
28.	4 Cl, 3-NO ₂	H	"	215	"
29.	3-OH	H	"	210	"
30.	4-OH	H	"	210	"
31.	2-OH	H	"	209	"
32.	4-CF ₃	H	"	177	"
33.	4-NHCOCH ₃	H	"	274	"
34.	3,4-(OMe) ₂	H	H,H	151	"
35.	2,4,6-(OMe) ₃	H	H,H	132	"
36.	2-OH	H	H,H	190	"
37.	3-OH	H	H,H	63	"
38.	4-OH	H	H,H	216	"
39.	3,4-(OH) ₂	H	H,H	201	"
40.	2-CH ₃	H	H,H	157	"
41.	3,4-(OCH ₂ Ph) ₂	H	Δ 2',3'	173	"
42.	3,4-O-CH ₂ -O-	H	"	185	"
43.	4-Cl	H	"	231	(+)

Compound No.	R ₅	R ₂	a	mp °C	Sign of Rotation
44.	4-Cl	H	$\Delta^{2',3'}$	231	(-)
45.	4-Cl,3-NO ₂	H	"	235	(+)
46.	4-Cl,3-NO ₂	H	"	235	(-)
47.	3-OMe	H	"	191	(+)
48.	3-OMe	H	"	191	(-)
49.	3,4-(OMe) ₂	H	"	195	(+)
50.	3,4-(OMe) ₂	H	"	195	(-)
51.	2,3-Cl ₂	H	"	217	(+)
52.	2,3-Cl ₂	H	"	217	(-)

TABLE 1A

Compounds of formula II in which R₃ = 4,6 - (OCH₃)₂

Compound No.	R ₁	a	R ₂	R ₄	mp °C	Sign of Rotation
1.	2-Thienyl	$\Delta^{2',3'}$	H	OH	179-180	(±)
2.	2-Furyl	"	H	OH		"
3.	4-Nitrophenyl	"	H	-OCOCH ₃	175	"
4.	4-Cyanophenyl	"	H	-OCOCH ₃	172	"
5.	4-Chlorophenyl	"	H	-OCOCH ₂ NH ₂ -HCl	152	"
6.	3,4-Dimethoxyphenyl	"	H	-OCOCH ₂ NH ₂ -HCl	136-138	"

- 5 The novel compounds of the present invention display interesting pharmacological activity when tested in pharmacological models; compound 4 of the above table will be used in the examples as a representative compound.

As shown in the examples, the instant compounds have antiinflammatory properties. The compounds are particularly useful to inhibit or antagonize the responses mediated by endogenous molecules such as lipxygenases and/or leukotrienes, interleukins and protein kinase C. The compounds of the invention, alone or in the form of a suitable formulation, are thus useful as medicaments in the treatment of inflammatory conditions, in particular chronic inflammatory conditions such as rheumatoid arthritis, osteoarthritis, asthma and malignancies.

Accordingly, another subject of the instant invention are the use and methods of use to treat and prevent the above-mentioned inflammatory conditions by administration of an active amount of one or more compounds of the instant invention. Furthermore, pharmaceuticals containing one or more compounds as explained above are a subject of this invention. Said pharmaceuticals can be produced and administered according to methods known in the art.

The following examples as well as the patent claims further illustrate the instant invention.

Example 1

Inhibition of leukotriene induced contraction of isolated guinea pig ileum.

Guinea pigs of either sex weighing 300-350 g were sensitized with a suspension of aluminium hydroxide gel and egg albumin. After 21 days, each animal was exposed to 0.5 % egg albumin aerosol in an air tight perspex chamber and only those animals which developed allergic bronchoconstriction were selected for further experiment.

The animals were tested for one week after antigenic exposure and then sacrificed by head blow and cutting carotid arteries. The lung was quickly removed and placed in aerated Tyrode solution kept at 37°C. The lung was cut into uniform strips and each strip was placed in an organ bath containing isolated guinea pig ileum connected to potentiometric recorder through isotonic transducer in the presence of Tyrode solution kept at 37°C. After stabilizing period of 30 minutes, the reactivity of ileum to histamine was confirmed by challenging it with 100 ng-200 ng/ml of histamine. The perfusion fluid was then replaced by Tyrode solution containing Atropine (10^{-7} M), Mepyramine maleate (10^{-7} M) and methylsergide (10^{-7} M). Three minutes later lung strip was challenged by egg albumin (25 µg/ml) and release of leukotrienes was monitored in terms of slow contraction of ileum. The ileum was allowed to contract for 10-15 minutes when a plateau was achieved. The test compound (compound 4 of table 1) was then added to observe the relaxation.

The specificity of leukotriene antagonism was determined by inducing contraction of guinea pig ileum with agonists like histamine, acetylcholine and KCl. Compounds having specific effect against lipoxygenase products induced contraction normally would not show any inhibition of histamine, acetylcholine and KCl induced contraction. The data are shown in table 2.

Table 2

Effect of Compound No. 4 on isolated guinea pig ileum precontracted with leukotrienes

Conc. (M)		% Relaxation	App. IC ₅₀ (M)
1.2	X 10 ⁻⁶	36.8	1.68 X 10 ⁻⁶
1.68	X 10 ⁻⁶	50.5	
2.4	X 10 ⁻⁶	62.4	
7.2	X 10 ⁻⁶	68.0	

No effect on histamine and KCl induced contraction up to 7.11×10^{-5} M.

Compound 4 as representative of the novel compounds of the present invention inhibits the contractions induced by leukotrienes.

Example 2

Inhibition of Cotton Pellet Granuloma in Rats:

This model permits the evaluation of a compound's potential to inhibit artificially induced granuloma. The implantation of carrageenin impregnated cotton pellets results in production of large well defined granuloma which are easily dissected. The potency of the compounds are assessed by measuring the reduction in granuloma tissue formation.

Preparation of Saline and Carrageenin Cotton Pellets:

Cotton wool pellets weighing 40 mg were used for sterilization. Half the number of pellets were dipped in saline and the remaining in 1 % aqueous solution (Viscarin® type 402, Marine Colloids Inc. Springfield) till they were soaked well, squeezed slightly to remove excess saline or carrageenin.

Pellets were dried overnight under a lamp. The pellets in the weight range of 42-44 mg were selected.

Animal Preparation:

Rats (in groups of 6, male or female, Charles River, Wistar, weighing 140-150 g) were anaesthetized with ether. The back was shaved and cleaned; swabbed with alcohol and one centimeter incision was made in the lower midback. A small channel was made bilaterally using a blunt forceps and one cotton pellet placed in each channel. Air from the incision was removed and the wound was stitched.

The test compound was prepared in 0.5 % carboxy methyl cellulose and was administered orally at a dose of 10, 20 and 30 mg/kg daily for seven days. Three hours after the administration of the last dose on day 7, animals were sacrificed. The pellets were removed by cutting the skin along the dorsal midline and peeling the skin away from the bodywall in both lateral directions. The pellets were weighed and then placed in drying oven at 140°C overnight. The dry weights were then recorded and the amount of granuloma was assessed by subtracting the original pellet weight from wet weights and dry weights. The data was evaluated using the difference of left and right weights (cf. table 3).

Table 3

Effect of Compound No. 4 on Cotton Pellet Granuloma in Rats.

Treatment	Dose mg/kg, p.o. X 5	% Inhibition of granuloma	
		Wet wt.	Dry wt.
Compound No. 4	10	21	35.6
	20	54	89.0
	30	64	82.8
Hydrocortisone	30	20.5	37.5

Compound 4 as representative of the compounds of the present invention inhibit the granuloma formation induced by carrageenin.

Example 3

Inhibition of Micro-anaphylactic shock of Guinea Pigs:

Guinea pigs of either sex weighing between 300-350 g were sensitized with egg albumin absorbed over $Al(OH)_3$ gel. After 21 days of sensitization, each animal was placed in an air tight perspex chamber and exposed to 0.5 % egg albumin aerosol through EEL atomizer. EEL atomizer was operated by connecting it to the pressurized air through water trap and dial type sphygmomanometer at the constant air pressure of 180 mm Hg. The time of onset of asthma in seconds and recovery period in minutes was noted.

Each animal was exposed to egg albumin aerosol at an interval of 15 days to maintain the consistency of the reactivity of animals to the antigen. After 3 such control exposures, animals were subjected to drug treatment. On the day of experiment one group of Guinea pig consisting of 10 animals was kept as control exposing them only to 0.5 % egg albumin aerosol. Another group of 10 guinea pigs

was treated with Indomethacin 10 mg/kg i.p. 30 mins. before the exposure to the antigen. Yet another group of 10 guinea pigs was pretreated with Indomethacin 10 mg/kg i.p. and 30 mins after Indomethacin pretreatment the test compound (20 mg/ip) was injected. Fifteen mins after the administration of the test compound the animals were exposed to 0.5 % egg albumin aerosol. Onset time of recovery period of each group was noted (cf. table 4).

Table 4

Effect of Compound No. 4 on microanaphylactic shock of guinea pigs

Treatment	Onset Time in secs.	Recovery period in mins.
Control group	75 + 8.7	37 + 3.4
Indomethacin treated group 10 mg/kg, i.p.	82.4 + 11.5	147.8 + 3.5
Compound 4, 20 mg/kg ⁻¹ , i.p. present invention + pretreatment with indomethacin, 10 mg/kg, i.p.	149.2 + 25.1	77.6 + 4.7

Compound 4 as the representative example of the novel compounds of the present invention protects the animals from bronchoconstriction induced by leukotrienes, subsequent to the exposure to egg albumin aerosol.

Example 4

Inhibition of IL-1 release human mononuclear cells:

Purification of mononuclear cells from human blood.

10 ml of human blood are carefully drawn from the antecubital vein using a syringe

containing 1 ml of a solution of 3.8 % sodium citrate. After dilution with 10 ml PM 16 (Serva, Heidelberg, FRG) and underlayering with 15 ml Lymphoprep[®] (Molter GmbH), the sample is centrifuged at 400 X g for 40 min at 20°C. The mononuclear cells forming a white ring between lymphoprep and plasma are carefully aspirated by a syringe, diluted with 1:1 with PM 16 and centrifuged again at 400 X g for 10 min. The supernatant is washed with 10 ml RPMI 1640 (Gibco, Berlin, FRG), containing additionally 300 mg/l L-glutamine, 25 mmol/l RPM 1640, containing additionally 300 mg/l L-glutamine, 25 mmol/l HEPES, 100 µg/ml streptomycin and 100 µg/ml penicillin. Finally, using a coulter counter IT the cell suspension is adjusted to 5×10^6 cells/ml. The cells consist of approx. 90 % lymphocytes and 10 % monocytes.

Stimulation of Interleukin 1 from human mononuclear cells in vitro:

10 µl DMSO/water (1:10, v/v), containing the test compound, is added to 480 µl of a suspension, containing 5×10^6 mononuclear cells. The synthesis of IL-1 is stimulated by the addition of 10 µl DMSO/water (1:10, v/v), containing 0,5 µg LPS (Salmonella abortus equi, Sigma). After incubation at 37°C for 18 hours the samples are cooled to 0°C and centrifuged for 1 min in a table centrifuge. 25 µl aliquots of the supernatant are assayed for IL-1 alpha activity using a commercially available ¹²⁵J-IL-1-alpha radioimmunoassay Kit (Amersham/UK), and for IL-1 beta in a similar way using the specific test kit. Control experiments are performed as described without test compound, or with cycloheximide as a test compound.

The effect of compound 4 as inhibitor of LPS stimulated IL-1 alpha (Approx. IC_{50} = 200 - 300 nmol/l), is shown in Fig. 1

Compound 4 as representative example of the compounds of the present invention inhibits LPS stimulated IL-1 alpha release from human mononuclear cells in vitro.

Compounds of the instant application are prepared as described below:

Example 5

Preparation of 1-(2,4,6-Trimethoxyphenyl)cyclohexene:

An example of formula V wherein $R_3 = 4,6\text{-dimethoxy}$, $R_2 = \text{CH}_3$.

- 5 2,4,6-Trimethoxybromobenzene (1 eqvt) is taken in a flame dried 3-necked flask under nitrogen. Dry tetrahydrofuran (THF) (983 ml) is added and the reaction mixture is cooled to -30°C . n-BuLi (1.3 eqvt.) in hexane (commercial) is added dropwise and after the addition the reaction mixture is stirred for 30 min. Thin layer chromatographic examination at this stage indicates completion of
- 10 metallation reaction. Cyclohexanone (1.1 eqvt.) diluted with equal volume of dry THF is added to the reaction mixture at -30°C and the reaction mixture stirred for another one hour at -30°C and later allowed to come to room temperature. Water (150 ml) was added and extracted with ethyl acetate. The ethyl acetate layer is dried over anhydrous sodium sulfate and concentrated.
- 15 The residue is taken in dichloromethane and stirred for 30 min with catalytic amount of p-toluenesulphonic acid (9 g). The dichloromethane layer is washed with sodium bicarbonate solution followed by water and dried. The residue was crystallised from Diisopropylether to give the title compound, m.p. 127°C . yield : 64.7%.

20 Example 6

Preparation of trans-(±)-2-(2,4,6-Trimethoxyphenyl) cyclohexanol:

An example of formula VI wherein $R_2 = \text{CH}_3$, $R_3 = 4,6\text{-dimethoxy}$ and $R_4 = \text{OH}$.

- A compound of formula V (from example 1) (1 eqvt.) is taken along with sodium borohydride (4 eqvt.) and dry THF (2,200 ml). The reaction mixture is cooled to
- 25 0°C under nitrogen and borontrifluoride etherate (5.1 eqvt.) was added dropwise. After the addition is complete, the temperature is raised to 50°C and

stirred for 30 min. The reaction mixture is cooled to room temperature and water is added dropwise to destroy excess diborane. The organoborane is oxidised by simultaneous addition of 30% H_2O_2 (248 ml) and 3M NaOH (248 ml) solution. After the addition the reaction mixture is heated at 50°C for 3 hours. After completion of oxidation, the reaction mixture is diluted with water and extracted with ethyl acetate. The ethyl acetate layer is dried and concentrated. The crude product is purified by flash chromatography on silica gel using 10% ethyl acetate in pet. ether, mp 123°C , yield : 52%.

Example 7

- 10 Preparation of *trans*-(\pm)-1-[3-(2-Acetoxy)cyclohexyl-2,4,6-trimethoxy]phenyl-1-ethanone:

Formula VII wherein $\text{R}_3 = 4,6\text{-dimethoxy}$, $\text{R}_2 = \text{CH}_3$ and $\text{R}_4 = \text{O-CO-CH}_3$.

- 15 The product from example 2 (1 eqvt.) is taken in dry methylene chloride (1520 ml). Acetic anhydride (25 eqvt) and phosphoric acid (152 ml) is added and stirred at room temperature for one hour. The reaction mixture is worked up by adding sodium carbonate solution till the reaction mixture is alkaline and extracted with dichloromethane. The organic layer is thoroughly washed with water and dried. The crude product after removal of the solvent is crystallised from pet. ether mp 87°C , yield : 84%.

20 Example 8

Preparation of *trans* - (\pm)-1-[3-(2-Acetoxy)cyclohexyl-4,6-dimethoxy-2-hydroxy]-phenyl-1-ethanone : Formula VII wherein $\text{R}_2 = \text{H}$, $\text{R}_3 = 4,6\text{-dimethoxy}$ and $\text{R}_4 = \text{O-CO-CH}_3$.

- 25 The product from example 3 (1 eqvt.) is taken in dry dichloromethan (5,450 ml) and cooled to 0°C . Borontribromide (1.1 eqvt.) is added with a syringe and stirred at 0°C for one hour. Water is added carefully and the product is extracted with ethyl acetate, washed with water, dried over anhydrous sodium

sulfate. The crude product is crystallised from ethyl acetate, mp 151°C, yield : 70-71%.

Example 9

Preparation of trans --(±)-2-[3-Acetyl-4,6-dimethoxy-2-hydroxy] phenylcyclo-
5 hexanol : Formula VII wherein $R_2 = H$, $R_3 = 4,6\text{-dimethoxy}$, $R_4 = OH$.

The product from example 4 (1 eqvt.) is stirred under nitrogen atmosphere with methanolic potassium hydroxide solution (20 eqvt., MeOH:water: :3:1) for six hours. The reaction mixture is acidified with dil HCl and the precipitate is filtered off, washed, dried and crystallised from ethylacetate, mp 161°C, yield :
10 88-89%.

Example 10

Preparation of trans-(±)-2-[4,6-Dimethoxy-2-hydroxy-3-(3-(4-chlorophenyl) prop-2-(E)-enoyl)] phenylcyclohexanol : Formula II wherein $R_1 = 4\text{-chlorophenyl}$, a= another bond, $R_2 = H$, $R_2=4,6\text{-dimethoxy}$ and $R_4 = OH$.

15 The product from example 5 (1 eqvt.) is stirred with 4-chloro benzaldehyde (3 eqvt.) and 10% alcoholic sodium hydroxide (30 eqvt.) at room temperature for 24 hours. The reaction mixture is acidified with dil HCl at 0°C to pH 5 and the orange precipitate is collected by filtration. Recrystallised from ethyl alcohol, mp 221°C yield : 68%.

20 Example 11

Preparation of trans -(±)-2-[4,6-Dimethoxy-2-hydroxy-3-(3-(4-chlorophenyl) propanoyl)] phenylcyclohexanol : Formula II wherein $R_1 = 4\text{-chlorophenyl}$, a= no bond, $R_2 = H$, $R_3=4,6\text{-dimethoxy}$ and $R_4 = OH$.

The product from example 6 is stirred with 10% pd/c (5 mol %) in ethyl alcohol
25 and under hydrogen overnight. The catalyst is filtered off and the solvent concentrated to give the product, mp 190°C, yield : 90%.

Example 12

An alternative preparation of trans-(±)-2-[2,4,6-trimethoxy] phenylcyclohexanol :
Formula VI wherein $R_2 = \text{CH}_3$, $R_3 = 4,6\text{-dimethoxy}$ and $R_4 = \text{OH}$.

2,4,6-Trimethoxybenzene (1 eqvt.), cyclohexene oxide (1.5 eqvt.) and dry
5 dichloromethane (840 ml) are taken in 3-necked r.b flask equipped with a
stirrer. The reaction mixture is cooled to -78°C and aluminum chloride (1.5
eqvt.) is added in small portions over a period of one hour. The stirring was
continued for an additional period of three hours. The reaction mixture is
worked up by addition of water and extracted with ethyl acetate. The crude
10 product is crystallised from petroleum ether, mp. 123°C , yield : 63-64 %.

Example 13

Resolution of (±)-trans-2-(2,4,6-trimethoxy) phenylcyclohexanol : a compound of
Formula VI wherein $R_2 = \text{H}$, $R_3 = 4,6\text{-dimethoxy}$ and $R_4 = \text{OH}$.

(±) trans-2-(2,4,6-trimethoxy) phenylcyclohexanol (50.0 g; 0.18797 mol), 3-nitro-
15 phthalic anhydride (26.299 g; 0.18797 mol) and pyridine (42.18 ml;
 2.78×0.18797 mol) are heated at 100° under N_2 atmosphere for 3h. Reaction
mixture is cooled to 0° , neutralised with 2N HCl and the product obtained
extracted with chloroform. The residue after evaporation of solvent is
crystallised from methanol (400 ml) to give the crystals of compound of the
20 Formula VI wherein R_4 is 3-nitrophthaloyloxy (59.0 g; m.p. $198\text{-}200^\circ$). The hemi
acid (0.1285 mol) is treated with (+) cinchonine (37.85 g; 0.1285 mol) in
methanol (250 ml) on steam bath for 30 minutes. Solvent removed at the
reduced pressure and the residual salt [96.5 g, OR (+) 84.75° (Hg, 578)]
crystallised from ethyl acetate-petether (1:1 1400 ml) to afford the crystals (45.0
25 g; OR (+) 75.11° (Hg, 578) and another liquor [50.0 g; OR (+) 97.30° (Hg, 578)].


The crystals (45.0 g) on further crystallisations (thrice) from ethyl acetate-pet
ether afford enriched cinchonine salt [31.0 g OR (+) 71.08° (Hg, 578)]. The

enriched salt on treatment with 2N HCl at 0° gives the resolved (-) compound of the Formula VI, wherein R₄ is 3-nitrophthaloyloxy [16.1 g; OR (-) 37.15° (Hg, 578). The hemi acid on hydrolysis with 7.5% KOH solution in methanol -water (1:2; 587.8 ml) at reflux temperature, followed by crystallisation of the product
5 from ethyl acetate - pet ether (24:160 ml) yields (-)-trans-2-(2,4,6-trimethoxy)phenylcyclohexanol [7.0 g; OR (-) 43.430 (Hg, 578)].

The mother liquor (50.0 g) is treated with 2N HCl at 0° and the product is subjected to crystallisations (thrice) from ethyl acetate-pet ether to give the crystals of the resolved (+) compound of the Formula VI; wherein R₄ is 3-
10 nitrophthaloyloxy [15.1 g; OR (+) 35.65° (Hg, 578)]. The hemi acid on hydrolysis with 7.5% KOH solution in methanol-water (1:2; 548.5 ml) at reflux temperature for 60h followed by crystallisation of the product from ethyl acetate-petether (25:150 ml) yields (+) trans-2-(2,4,6-trimethoxy)phenylcyclohexanol [7.24 g; OR (+) 42.30° (Hg, 578)].


THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. Compounds of formula I







wherein


R_1 denotes C_1 - C_6 -alkyl, substituted C_1 - C_6 -alkyl, $C(O)O$ - C_1 - C_4 -alkyl, $C(O)OH$, or a residue selected from



wherein R_5 is one, two, three or four of the residues which are independent from each other H, C_1 - C_6 -alkyl, substituted C_1 - C_6 -alkyl, hydroxy, C_1 - C_6 -alkoxy, C_1 - C_4 -alkyl-carboxy, cyano, $-NHC(O)C_1$ - C_3 -alkyl, $-OC_1$ - C_3 -alkyl-phenyl, $-OCH_2-O-O-C_1$ - C_4 -alkyl, $-O-C(O)-C_1$ - C_4 -alkyl, $-C(O)-O-C_1$ - C_4 -alkyl, halogens, amino, nitro, $-NH$ - C_1 - C_4 -alkyl, $-N-(C_1-C_4\text{-alkyl})_2$ and $-C_1$ - C_4 -alkyl- R_6 wherein R_6 is a residue selected from



and



X is O, S, N-H, N-C₁-C₆-alkyl;

R₂ is H, C₁-C₆-alkyl, -C(O)-C₁-C₆-alkyl;

R₃ is one, two or three of the residues which are independent from each other
H, C₁-C₆-alkyl, -C(O)-C₁-C₆-alkyl, -C(O)-O-C₁-C₆-alkyl, OH, O-C₁-C₆-alkyl,
-O-C(O)-C₁-C₆-alkyl, halogen;


R₄ is H, -OH, -O-C₁-C₆-alkyl, -O-C(O)-C₁-C₆-alkyl, -C(O)-OH, -C(O)-O-C₁-C₆-alkyl,

$\text{O}-\overset{\text{O}}{\parallel}\text{C}-(\text{C}_1-\text{C}_4\text{-alkyl})-\text{NH}_2$, $\text{O}-\overset{\text{O}}{\parallel}\text{C}-(\text{C}_1-\text{C}_4\text{-alkyl})-\text{NH}-(\text{C}_1-\text{C}_4\text{-alkyl})$, $\text{O}-\overset{\text{O}}{\parallel}\text{C}-(\text{C}_1-\text{C}_4\text{-alkyl})-\text{N}-(\text{C}_1-\text{C}_4\text{-alkyl})_2$,

n = 0, 1 or 2 and

'a' represents an optional additional single bond.


2. Compounds as claimed in claim 1, wherein said compounds have the formula




(III)

wherein R_1 , R_2 , R_3 , R_4 and a are as ~~previously defined.~~ ^{defined in claim 1.}


3. Compounds of formula I as claimed in claims 1 or 2, in which R_1 is



10 R_5 denoting H, C_1 - C_6 -alkyl, substituted C_1 - C_6 -alkyl, hydroxy, C_1 - C_3 -alkoxy, halogen, C_1 - C_4 -alkyl- R_6 wherein R_6 stands for




or



R_4 denotes H, OH or $-O-C(=O)-(C_1-C_4\text{-alkyl})-NH_2$;

20 X stands for O, NH, S, N- C_1 - C_6 -alkyl and a stands for an optional additional bond.

4. Compounds as claimed in one or more of claims 1 - 3 wherein said compounds have the formula III



(III)

wherein


R_2 is H or C_1-C_3 -alkyl,

R_5 denotes one or two halogens or one or two C_1-C_6 -alkyl or C_1-C_3 -alkoxy groups ^{one or two}
^{one C_1-C_6 -alkyl and one C_1-C_3 -alkoxy group}
 and Δ denotes an optional additional single bond.

5

5. A process for the production of compounds as claimed in claim 1 wherein a compound of formula V


10



15

A) is converted into a compound of formula VI, R_4 denoting OH

20




25

- by treatment with a borane-solvent-complex followed by oxidation or
- B) to get a compound of formula VI a compound of formula V is treated with a peracid and the epoxide thus produced is treated with a hydride reagent or
- C) the compound of formula VI is produced by condensation of a suitable arene with cyclohexene oxide in the presence of an acid catalyst and

30



- D) a compound of formula VI is treated with acetic anhydride and a mineral acid to give a compound of formula VII,



wherein R_2 is methyl and R_4 is $O-C(O)-Me$ and

- 15
- E) a compound of formula VII as described under D) is demethylated by treatment with a Lewis acid or a demethylating agent to give a compound of formula VII R_2 denoting H and R_4 denoting $OC(O)Me$ and
- 20
- F) a compound of formula VII R_2 denoting H and R_4 denoting OH is produced by treatment of a compound produced under E) with dilute alkali, and
- G) the compound of formula VII is converted into a compound of formula I ($a =$ additional bond) by treatment with an appropriate aldehyde in the presence of a base and the compound of formula I ($a =$ no additional bond) is produced by hydrogenation of the compound of formula I ($a =$ additional bond), R_1 , R_2 and R_3 where not explained explicitly having the meaning as defined in claim 1.

25

~~6. A pharmaceutical containing an active amount of at least one compound as claimed in claims 1 - 4.~~

30

~~7. The use of compounds as claimed in one or more of claims 1 - 4 for the prevention and/or treatment of inflammatory conditions, in particular chronic inflammatory conditions.~~



6. A pharmaceutical containing an active amount of at least one compound as claimed in any one of claims 1 to 4 in adjunct with suitable carriers and/or excipients.

7. A method of preventing and/or treating inflammatory conditions comprising administering to a patient requiring such treatment an effective amount of a compound as claimed in any one of claims 1 to 4.

8. A process for the production of a pharmaceutical as claimed in claim 6, wherein one or more compounds as claimed in claims 1 - 4 are admixed with suitable pharmaceutical auxiliaries and/or excipients.

DATED this 15th day of June, 1995

HOECHST AKTIENGESELLSCHAFT

WATERMARK PATENT & TRADEMARK ATTORNEYS
290 BURWOOD ROAD
HAWTHORN VICTORIA 3122
AUSTRALIA




24012

959

00


Abstract of the disclosure:

Compounds of formula I, wherein



the substituents R_1 - R_4 and a have the given meaning show an activity against inflammatory conditions.

15



1/1

31847/93